BioXcel Therapeutics Files 8-K
Ticker: BTAI · Form: 8-K · Filed: Jul 21, 2025 · CIK: 1720893
Sentiment: neutral
Topics: 8-K, corporate-event
TL;DR
BXcel filed an 8-K on 7/21/25 - other events.
AI Summary
BioXcel Therapeutics, Inc. filed an 8-K on July 21, 2025, reporting other events. The company, incorporated in Delaware with its principal executive offices in New Haven, CT, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a corporate event or update for BioXcel Therapeutics, Inc., which may be relevant to investors and stakeholders tracking the company's progress.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose specific material financial or operational changes that would immediately indicate high risk.
Key Players & Entities
- BioXcel Therapeutics, Inc. (company) — Registrant
- July 21, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New Haven, CT (location) — Address of principal executive offices
- 203-643-8060 (phone_number) — Registrant's telephone number
FAQ
What is the specific nature of the 'Other Events' reported in this 8-K filing?
The provided text does not specify the exact nature of the 'Other Events'; it only indicates that this section of the 8-K is being utilized.
When was this 8-K filing submitted?
The filing was submitted on July 21, 2025.
What is BioXcel Therapeutics, Inc.'s principal business address?
The principal executive offices are located at 555 Long Wharf Drive, New Haven, CT 06511.
In which state was BioXcel Therapeutics, Inc. incorporated?
The company was incorporated in Delaware.
What is the Commission File Number for BioXcel Therapeutics, Inc.?
The Commission File Number is 001-38410.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding BioXcel Therapeutics, Inc. (BTAI).